NO314934B1 - Heterocykliske metallproteaseinhibitorer - Google Patents

Info

Publication number

NO314934B1

NO314934B1 NO19990759A NO990759A NO314934B1 NO 314934 B1 NO314934 B1 NO 314934B1 NO 19990759 A NO19990759 A NO 19990759A NO 990759 A NO990759 A NO 990759A NO 314934 B1 NO314934 B1 NO 314934B1

Authority

NO

Norway

Prior art keywords

mmol

methoxyphenyl

compounds

substituted

sulfonyl

Prior art date

1996-08-28

Links

• Espacenet
• Global Dossier
• Discuss

• 125000000623 heterocyclic group Chemical group 0.000 title claims description 16
• 229910052751 metal Inorganic materials 0.000 title description 3
• 239000002184 metal Substances 0.000 title description 3
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims description 137
• 102000005741 Metalloproteases Human genes 0.000 claims description 70
• 108010006035 Metalloproteases Proteins 0.000 claims description 70
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 63
• 238000011282 treatment Methods 0.000 claims description 45
• 230000000694 effects Effects 0.000 claims description 35
• 208000035475 disorder Diseases 0.000 claims description 33
• 201000010099 disease Diseases 0.000 claims description 30
• 125000004432 carbon atom Chemical group C* 0.000 claims description 16
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
• 239000001257 hydrogen Substances 0.000 claims description 12
• 229910052739 hydrogen Inorganic materials 0.000 claims description 12
• 238000002360 preparation method Methods 0.000 claims description 11
• 230000003287 optical effect Effects 0.000 claims description 8
• 150000003839 salts Chemical class 0.000 claims description 8
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
• 125000003545 alkoxy group Chemical group 0.000 claims description 6
• 150000002148 esters Chemical class 0.000 claims description 6
• 150000001408 amides Chemical class 0.000 claims description 5
• 125000004043 oxo group Chemical group O=* 0.000 claims description 5
• 239000008194 pharmaceutical composition Substances 0.000 claims description 5
• 150000003949 imides Chemical class 0.000 claims description 4
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
• 125000002883 imidazolyl group Chemical group 0.000 claims description 2
• 239000000203 mixture Substances 0.000 description 79
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 41
• 239000000243 solution Substances 0.000 description 41
• 239000003921 oil Substances 0.000 description 32
• 235000019198 oils Nutrition 0.000 description 32
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 31
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
• 239000003112 inhibitor Substances 0.000 description 30
• 238000000034 method Methods 0.000 description 26
• -1 methoxy, ethoxy, propoxy Chemical group 0.000 description 23
• 239000011541 reaction mixture Substances 0.000 description 23
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 22
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
• 230000002829 reductive effect Effects 0.000 description 21
• 239000003937 drug carrier Substances 0.000 description 18
• 239000000047 product Substances 0.000 description 18
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
• 239000007787 solid Substances 0.000 description 16
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
• 235000019439 ethyl acetate Nutrition 0.000 description 14
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
• 125000003118 aryl group Chemical group 0.000 description 13
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 13
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 12
• 108090000790 Enzymes Proteins 0.000 description 12
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• 125000000217 alkyl group Chemical group 0.000 description 12
• 229940088598 enzyme Drugs 0.000 description 12
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
• 241000124008 Mammalia Species 0.000 description 11
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
• 230000015556 catabolic process Effects 0.000 description 11
• 229910052938 sodium sulfate Inorganic materials 0.000 description 11
• 235000011152 sodium sulphate Nutrition 0.000 description 11
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 11
• 241000282414 Homo sapiens Species 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 239000012074 organic phase Substances 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 9
• 239000002552 dosage form Substances 0.000 description 9
• 239000003480 eluent Substances 0.000 description 9
• 125000005842 heteroatom Chemical group 0.000 description 9
• 206010039073 rheumatoid arthritis Diseases 0.000 description 9
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
• 125000004429 atom Chemical group 0.000 description 8
• 125000002837 carbocyclic group Chemical group 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 239000000284 extract Substances 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
• 230000002265 prevention Effects 0.000 description 8
• 239000011734 sodium Substances 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 7
• 239000007832 Na2SO4 Substances 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 125000000753 cycloalkyl group Chemical group 0.000 description 7
• 125000001072 heteroaryl group Chemical group 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 239000000741 silica gel Substances 0.000 description 7
• 229910002027 silica gel Inorganic materials 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
• DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 238000010168 coupling process Methods 0.000 description 6
• 239000006196 drop Substances 0.000 description 6
• 239000000975 dye Substances 0.000 description 6
• 235000019253 formic acid Nutrition 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 239000000314 lubricant Substances 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• 239000003475 metalloproteinase inhibitor Substances 0.000 description 6
• 201000008482 osteoarthritis Diseases 0.000 description 6
• 238000007911 parenteral administration Methods 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 108090000623 proteins and genes Proteins 0.000 description 6
• 125000001424 substituent group Chemical group 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 230000000699 topical effect Effects 0.000 description 6
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
• 102000029816 Collagenase Human genes 0.000 description 5
• 108060005980 Collagenase Proteins 0.000 description 5
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 206010027476 Metastases Diseases 0.000 description 5
• 102000035195 Peptidases Human genes 0.000 description 5
• 108091005804 Peptidases Proteins 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• 101710172711 Structural protein Proteins 0.000 description 5
• 125000003710 aryl alkyl group Chemical group 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 239000003995 emulsifying agent Substances 0.000 description 5
• 239000000796 flavoring agent Substances 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 235000011187 glycerol Nutrition 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 230000009401 metastasis Effects 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 238000007634 remodeling Methods 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 239000000600 sorbitol Substances 0.000 description 5
• 235000010356 sorbitol Nutrition 0.000 description 5
• 235000019698 starch Nutrition 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• SUSMVCKSLVPRCL-QGZVFWFLSA-N 1-benzyl-3-(4-methoxy-benzenesulfonyl)-6-oxo-hexahydro-pyrimidine-4-carboxylic acid hydroxyamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(=O)NO)CC(=O)N(CC=2C=CC=CC=2)C1 SUSMVCKSLVPRCL-QGZVFWFLSA-N 0.000 description 4
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• VTARNTUWIGSACU-UHFFFAOYSA-N C(C)OC(C(C(C(=O)O)(C)C)NS(=O)(=O)C1=CC=C(C=C1)OC)=O Chemical compound C(C)OC(C(C(C(=O)O)(C)C)NS(=O)(=O)C1=CC=C(C=C1)OC)=O VTARNTUWIGSACU-UHFFFAOYSA-N 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 4
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 208000025865 Ulcer Diseases 0.000 description 4
• 206010064996 Ulcerative keratitis Diseases 0.000 description 4
• 235000010443 alginic acid Nutrition 0.000 description 4
• 239000000783 alginic acid Substances 0.000 description 4
• 229920000615 alginic acid Polymers 0.000 description 4
• 229960001126 alginic acid Drugs 0.000 description 4
• 150000004781 alginic acids Chemical class 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• ULNVEIDJNVOYLS-XMMPIXPASA-N benzyl (4r)-1-benzyl-3-(4-methoxyphenyl)sulfonyl-6-oxo-1,3-diazinane-4-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(=O)OCC=2C=CC=CC=2)CC(=O)N(CC=2C=CC=CC=2)C1 ULNVEIDJNVOYLS-XMMPIXPASA-N 0.000 description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 239000001768 carboxy methyl cellulose Substances 0.000 description 4
• 235000010980 cellulose Nutrition 0.000 description 4
• 229920002678 cellulose Polymers 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 239000000460 chlorine Substances 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 239000000945 filler Substances 0.000 description 4
• 235000003599 food sweetener Nutrition 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 230000037390 scarring Effects 0.000 description 4
• 238000010898 silica gel chromatography Methods 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 108091007196 stromelysin Proteins 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• 239000003765 sweetening agent Substances 0.000 description 4
• 238000007910 systemic administration Methods 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 239000000454 talc Substances 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 229910052623 talc Inorganic materials 0.000 description 4
• 238000005303 weighing Methods 0.000 description 4
• MQFAABVDVWSBEA-GOSISDBHSA-N (2R)-2-benzyl-2-[(4-methoxyphenyl)sulfonylamino]butanedioic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N[C@](CC(O)=O)(C(O)=O)CC1=CC=CC=C1 MQFAABVDVWSBEA-GOSISDBHSA-N 0.000 description 3
• AKPYSHWTFFKMAQ-XMMPIXPASA-N (4r)-1-benzyl-3-(4-methoxyphenyl)sulfonyl-6-oxo-n-phenylmethoxy-1,3-diazinane-4-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(=O)NOCC=2C=CC=CC=2)CC(=O)N(CC=2C=CC=CC=2)C1 AKPYSHWTFFKMAQ-XMMPIXPASA-N 0.000 description 3
• LWMHXPZOLPPFBE-UHFFFAOYSA-N 1-(4-methoxyphenyl)sulfonyl-5-(1-methylimidazol-4-yl)sulfonyl-3h-diazepine-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1N(C(O)=O)CC=C(S(=O)(=O)C=2N=CN(C)C=2)C=C1 LWMHXPZOLPPFBE-UHFFFAOYSA-N 0.000 description 3
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 241000416162 Astragalus gummifer Species 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 239000001856 Ethyl cellulose Substances 0.000 description 3
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
• 108010026132 Gelatinases Proteins 0.000 description 3
• 102000013382 Gelatinases Human genes 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 235000021355 Stearic acid Nutrition 0.000 description 3
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
• 229920001615 Tragacanth Polymers 0.000 description 3
• 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 3
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
• 125000002252 acyl group Chemical group 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 238000002399 angioplasty Methods 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 125000004104 aryloxy group Chemical group 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 235000011132 calcium sulphate Nutrition 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 229960002424 collagenase Drugs 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 210000004087 cornea Anatomy 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 235000019325 ethyl cellulose Nutrition 0.000 description 3
• 229920001249 ethyl cellulose Polymers 0.000 description 3
• 230000003176 fibrotic effect Effects 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 208000024693 gingival disease Diseases 0.000 description 3
• 150000004820 halides Chemical class 0.000 description 3
• 125000004404 heteroalkyl group Chemical group 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 229920000609 methyl cellulose Polymers 0.000 description 3
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 208000028169 periodontal disease Diseases 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 229920005862 polyol Polymers 0.000 description 3
• 150000003077 polyols Chemical class 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000008159 sesame oil Substances 0.000 description 3
• 235000011803 sesame oil Nutrition 0.000 description 3
• 210000001626 skin fibroblast Anatomy 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• 239000008117 stearic acid Substances 0.000 description 3
• 239000001384 succinic acid Substances 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• KEFAFZZUSORWFQ-UHFFFAOYSA-N tert-butyl 1h-1,4-diazepine-7-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=NC=CN1 KEFAFZZUSORWFQ-UHFFFAOYSA-N 0.000 description 3
• 238000011200 topical administration Methods 0.000 description 3
• 235000010487 tragacanth Nutrition 0.000 description 3
• 239000000196 tragacanth Substances 0.000 description 3
• 229940116362 tragacanth Drugs 0.000 description 3
• 235000015112 vegetable and seed oil Nutrition 0.000 description 3
• 239000008158 vegetable oil Substances 0.000 description 3
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
• ROTJAERMJDGJMY-AWEZNQCLSA-N (2s)-2-[2-hydroxyethyl-(4-methoxyphenyl)sulfonylamino]-2-methyl-4-sulfanylbutanoic acid Chemical compound COC1=CC=C(S(=O)(=O)N(CCO)[C@@](C)(CCS)C(O)=O)C=C1 ROTJAERMJDGJMY-AWEZNQCLSA-N 0.000 description 2
• NKPGARMEUMQZTB-QGZVFWFLSA-N (4r)-1-benzyl-3-(4-methoxyphenyl)sulfonyl-6-oxo-1,3-diazinane-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(O)=O)CC(=O)N(CC=2C=CC=CC=2)C1 NKPGARMEUMQZTB-QGZVFWFLSA-N 0.000 description 2
• UBDQAUSDZLOVJM-UHFFFAOYSA-N 1,5-bis[(4-methoxyphenyl)sulfonyl]-3h-diazepine-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1N(C(O)=O)CC=C(S(=O)(=O)C=2C=CC(OC)=CC=2)C=C1 UBDQAUSDZLOVJM-UHFFFAOYSA-N 0.000 description 2
• QXXUBPGYFQRIOA-UHFFFAOYSA-N 1-(4-methoxyphenyl)sulfonyl-3h-diazepine-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1N(C(O)=O)CC=CC=C1 QXXUBPGYFQRIOA-UHFFFAOYSA-N 0.000 description 2
• WJCVVZAJBQMQML-UHFFFAOYSA-N 1-(4-methoxyphenyl)sulfonyl-5-phenylmethoxycarbonyl-3h-diazepine-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1N(C(O)=O)CC=C(C(=O)OCC=2C=CC=CC=2)C=C1 WJCVVZAJBQMQML-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• 102000002322 Egg Proteins Human genes 0.000 description 2
• 108010000912 Egg Proteins Proteins 0.000 description 2
• 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 2
• 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
• 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
• 208000022873 Ocular disease Diseases 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
• 206010036600 Premature labour Diseases 0.000 description 2
• 201000002154 Pterygium Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 240000006474 Theobroma bicolor Species 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 108010003059 aggrecanase Proteins 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 125000000129 anionic group Chemical group 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• TXGMXTDBBGDLBK-HSZRJFAPSA-N benzyl (2r)-4-(benzylamino)-2-[(4-methoxyphenyl)sulfonylamino]-4-oxobutanoate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N[C@@H](C(=O)OCC=1C=CC=CC=1)CC(=O)NCC1=CC=CC=C1 TXGMXTDBBGDLBK-HSZRJFAPSA-N 0.000 description 2
• CZPWRCFDXUESBK-UHFFFAOYSA-N benzyl 2-(hydroxycarbamoyl)-1-(4-methoxyphenyl)sulfonyl-3h-diazepine-5-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1N(C(=O)NO)CC=C(C(=O)OCC=2C=CC=CC=2)C=C1 CZPWRCFDXUESBK-UHFFFAOYSA-N 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 210000004027 cell Anatomy 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 235000005687 corn oil Nutrition 0.000 description 2
• 239000002285 corn oil Substances 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 235000012343 cottonseed oil Nutrition 0.000 description 2
• 239000002385 cottonseed oil Substances 0.000 description 2
• 239000000287 crude extract Substances 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• AUHBCNJHXCDLMK-UHFFFAOYSA-N diazepine-1-carboxamide Chemical compound NC(=O)N1C=CC=CC=N1 AUHBCNJHXCDLMK-UHFFFAOYSA-N 0.000 description 2
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• IDMKSJGYFLSKBM-UHFFFAOYSA-N ditert-butyl 1-(4-methoxyphenyl)sulfonyl-3h-diazepine-2,5-dicarboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1N(C(=O)OC(C)(C)C)CC=C(C(=O)OC(C)(C)C)C=C1 IDMKSJGYFLSKBM-UHFFFAOYSA-N 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000008393 encapsulating agent Substances 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
• 239000001761 ethyl methyl cellulose Substances 0.000 description 2
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 206010016165 failure to thrive Diseases 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 208000007565 gingivitis Diseases 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 229910052736 halogen Inorganic materials 0.000 description 2
• 150000002367 halogens Chemical class 0.000 description 2
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
• 239000003906 humectant Substances 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 230000001788 irregular Effects 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 231100000053 low toxicity Toxicity 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
• 229960002216 methylparaben Drugs 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 239000002324 mouth wash Substances 0.000 description 2
• 229940051866 mouthwash Drugs 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• SLLGDLWSTUGQND-UHFFFAOYSA-N n-hydroxy-4-(4-methoxyphenyl)sulfonylthiazepine-5-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1=C(C(=O)NO)C=CSN=C1 SLLGDLWSTUGQND-UHFFFAOYSA-N 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 239000006186 oral dosage form Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 210000004681 ovum Anatomy 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 201000001245 periodontitis Diseases 0.000 description 2
• 230000004526 pharmaceutical effect Effects 0.000 description 2
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004344 phenylpropyl group Chemical group 0.000 description 2
• 239000002504 physiological saline solution Substances 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 208000026440 premature labor Diseases 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 235000013772 propylene glycol Nutrition 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 150000003335 secondary amines Chemical class 0.000 description 2
• 238000007086 side reaction Methods 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• 150000003512 tertiary amines Chemical class 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 230000008354 tissue degradation Effects 0.000 description 2
• 230000007838 tissue remodeling Effects 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 230000036269 ulceration Effects 0.000 description 2
• NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
• LCGGNNJLQZPEFF-HNNXBMFYSA-N (2R)-3-tert-butyl-N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-oxo-1,3-diazinane-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NO)N(C(C)(C)C)C(=O)CC1 LCGGNNJLQZPEFF-HNNXBMFYSA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
• MPXVVFUPVRYMJK-UHFFFAOYSA-N 1-benzyl-n-hydroxy-3-(4-methoxyphenyl)sulfonyl-5,5-dimethyl-6-oxo-1,3-diazinane-4-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C(C(=O)NO)C(C)(C)C(=O)N(CC=2C=CC=CC=2)C1 MPXVVFUPVRYMJK-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• KXUGUWTUFUWYRS-UHFFFAOYSA-N 1-methylimidazole-4-sulfonyl chloride Chemical compound CN1C=NC(S(Cl)(=O)=O)=C1 KXUGUWTUFUWYRS-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
• RILLZYSZSDGYGV-UHFFFAOYSA-N 2-(propan-2-ylamino)ethanol Chemical compound CC(C)NCCO RILLZYSZSDGYGV-UHFFFAOYSA-N 0.000 description 1
• DBTWOTKWIVISQR-UHFFFAOYSA-N 2-bromopropan-1-ol Chemical compound CC(Br)CO DBTWOTKWIVISQR-UHFFFAOYSA-N 0.000 description 1
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
• QIZPONOMFWAPRR-UHFFFAOYSA-N 4-phenoxybenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1OC1=CC=CC=C1 QIZPONOMFWAPRR-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 241000224422 Acanthamoeba Species 0.000 description 1
• 206010048998 Acute phase reaction Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 208000003120 Angiofibroma Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• MACYKLOHJXJLKB-TYZXPVIJSA-N C1=CC(OC)=CC=C1S(=O)(=O)C1N[C@@H](C(=O)NO)N(C(C)C)C(=O)C1 Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1N[C@@H](C(=O)NO)N(C(C)C)C(=O)C1 MACYKLOHJXJLKB-TYZXPVIJSA-N 0.000 description 1
• KKELGEXGARZPDY-CYBMUJFWSA-N C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NO)N(C)C(=O)CC1 Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NO)N(C)C(=O)CC1 KKELGEXGARZPDY-CYBMUJFWSA-N 0.000 description 1
• KETSDILBAFJYJX-SFHVURJKSA-N C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NO)N(C2CCCCC2)C(=O)CC1 Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@H](C(=O)NO)N(C2CCCCC2)C(=O)CC1 KETSDILBAFJYJX-SFHVURJKSA-N 0.000 description 1
• DJCFLPBFBODFKA-OAHLLOKOSA-N C1CC(=O)N(CCOC)[C@@H](C(=O)NO)N1S(=O)(=O)C1=CC=C(OC)C=C1 Chemical compound C1CC(=O)N(CCOC)[C@@H](C(=O)NO)N1S(=O)(=O)C1=CC=C(OC)C=C1 DJCFLPBFBODFKA-OAHLLOKOSA-N 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• 208000009043 Chemical Burns Diseases 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 206010010984 Corneal abrasion Diseases 0.000 description 1
• 208000028006 Corneal injury Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 241000271532 Crotalus Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 101800001224 Disintegrin Proteins 0.000 description 1
• 108700021041 Disintegrin Proteins 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 241001125671 Eretmochelys imbricata Species 0.000 description 1
• 229920003134 Eudragit® polymer Polymers 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• FFFHZYDWPBMWHY-UHFFFAOYSA-N HOMOCYSTEINE Chemical compound OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 244000062730 Melissa officinalis Species 0.000 description 1
• 235000010654 Melissa officinalis Nutrition 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 208000037099 Prosthesis Failure Diseases 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 206010039105 Rhinoviral infections Diseases 0.000 description 1
• 241000220010 Rhode Species 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 101710204001 Zinc metalloprotease Proteins 0.000 description 1
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000004658 acute-phase response Effects 0.000 description 1
• 125000004442 acylamino group Chemical group 0.000 description 1
• 125000004423 acyloxy group Chemical group 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000005256 alkoxyacyl group Chemical group 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 125000005336 allyloxy group Chemical group 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004103 aminoalkyl group Chemical group 0.000 description 1
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000002924 anti-infective effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000000729 antidote Substances 0.000 description 1
• 229940075522 antidotes Drugs 0.000 description 1
• 239000002518 antifoaming agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 229940125687 antiparasitic agent Drugs 0.000 description 1
• 239000003096 antiparasitic agent Substances 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 238000007080 aromatic substitution reaction Methods 0.000 description 1
• 210000001188 articular cartilage Anatomy 0.000 description 1
• 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
• 125000001769 aryl amino group Chemical group 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
• 239000012965 benzophenone Substances 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 150000001728 carbonyl compounds Chemical class 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 125000004181 carboxyalkyl group Chemical group 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 206010061592 cardiac fibrillation Diseases 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• 229940112822 chewing gum Drugs 0.000 description 1
• 235000015218 chewing gum Nutrition 0.000 description 1
• 235000015111 chews Nutrition 0.000 description 1
• 150000003841 chloride salts Chemical class 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 238000002967 competitive immunoassay Methods 0.000 description 1
• 238000011970 concomitant therapy Methods 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 229940124558 contraceptive agent Drugs 0.000 description 1
• 239000003433 contraceptive agent Substances 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000002826 coolant Substances 0.000 description 1
• 238000010219 correlation analysis Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960005168 croscarmellose Drugs 0.000 description 1
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
• 125000002592 cumenyl group Chemical group C1(=C(C=CC=C1)*)C(C)C 0.000 description 1
• 125000004093 cyano group Chemical group *C#N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• QRKPPWPLSQRGSU-UHFFFAOYSA-N diazepine-1-carboxylic acid Chemical compound OC(=O)N1C=CC=CC=N1 QRKPPWPLSQRGSU-UHFFFAOYSA-N 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 208000007784 diverticulitis Diseases 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000000921 elemental analysis Methods 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 238000003821 enantio-separation Methods 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 238000006266 etherification reaction Methods 0.000 description 1
• FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 1
• 229960004667 ethyl cellulose Drugs 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 230000002600 fibrillogenic effect Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 230000003779 hair growth Effects 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 125000004474 heteroalkylene group Chemical group 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 239000003752 hydrotrope Substances 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000012606 in vitro cell culture Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000012442 inert solvent Substances 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 230000035990 intercellular signaling Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 229940041616 menthol Drugs 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• FIYFPLIZBPVGNT-UHFFFAOYSA-N methyl 4-(4-methoxyphenyl)sulfonylthiazepine-5-carboxylate Chemical compound C1=NSC=CC(C(=O)OC)=C1S(=O)(=O)C1=CC=C(OC)C=C1 FIYFPLIZBPVGNT-UHFFFAOYSA-N 0.000 description 1
• 150000004702 methyl esters Chemical class 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• CDHRVOKWLXOXRZ-UHFFFAOYSA-N n,n'-dibenzyl-n'-ethylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CC)CCNCC1=CC=CC=C1 CDHRVOKWLXOXRZ-UHFFFAOYSA-N 0.000 description 1
• MJUKPBJXOAZZNS-UHFFFAOYSA-N n-hydroxy-1,5-bis[(4-methoxyphenyl)sulfonyl]-3h-diazepine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1N(C(=O)NO)CC=C(S(=O)(=O)C=2C=CC(OC)=CC=2)C=C1 MJUKPBJXOAZZNS-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000008481 normal tissue growth Effects 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 206010033103 otosclerosis Diseases 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• WIPLNCYPGHUSGF-UHFFFAOYSA-N prop-2-enyl 2-bromo-2-methylpropanoate Chemical compound CC(C)(Br)C(=O)OCC=C WIPLNCYPGHUSGF-UHFFFAOYSA-N 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 238000007127 saponification reaction Methods 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 208000013223 septicemia Diseases 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 230000037380 skin damage Effects 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• 239000007916 tablet composition Substances 0.000 description 1
• KFJFUHZECWUJHM-UHFFFAOYSA-N tert-butyl 1,5-bis[(4-methoxyphenyl)sulfonyl]-3h-diazepine-2-carboxylate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1N(C(=O)OC(C)(C)C)CC=C(S(=O)(=O)C=2C=CC(OC)=CC=2)C=C1 KFJFUHZECWUJHM-UHFFFAOYSA-N 0.000 description 1
• GOLLIHAQQIQRTQ-UHFFFAOYSA-N tert-butyl 1,5-dibenzyl-3h-diazepine-2-carboxylate Chemical compound C1=CN(CC=2C=CC=CC=2)N(C(=O)OC(C)(C)C)CC=C1CC1=CC=CC=C1 GOLLIHAQQIQRTQ-UHFFFAOYSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 230000037303 wrinkles Effects 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 125000005023 xylyl group Chemical group 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1